Clinical Oncology
Volume 22, Issue 4 , Pages 289-293 , May 2010

Review of Testing and Use of Adjuvant Trastuzumab across a Cancer Network — Are We Treating the Right Patients?

Received 15 January 2010 ,Revised 15 February 2010 ,Accepted 24 February 2010.

References 

  1. Office for National Statistics . Cancer statistics registrations: registrations of cancer diagnosed in 2006, England. Series MB1 no.37. London: Office for National Statistics; 2009;
  2. Nielsen DL, Andersson M, Kamby C, et al. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat Rev. 2009;35:121–136
  3. Sauter G, Lee J, Bartlett JM, et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009;27(8):1323–1333
  4. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–182
  5. Smith I, Procter M, Gelber RD, et al. Two-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369(9555):29–36
  6. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–1684
  7. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study. Presented at the 32nd CTRC-AACR San Antonio Breast Cancer Symposium. 9–13 December 2009. San Antonio, TX. Abstract 62.
  8. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354(8):809–820
  9. Spielmann M, Roche H, Machiels JP, et al. Trastuzumab following adjuvant chemotherapy in node positive, HER2-positive breast cancer patients: 4 year follow-up results of the PACS-04 trial In: 31st San Antonio Breast Cancer Symposium, San Antonio, Texas, 2007.
  10. National Institute for Health and Clinical Excellence (NICE) . Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer. London: National Institute for Health and Clinical Excellence; 2006;
  11. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat. 1992;22(3):207–219
  12. Curigliano G, Viale G, Bagnardi V, et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol. 2009;27(34):5693–5699
  13. Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009;27(34):5700–5706
  14. Vogel CL, Cobleigh MA, Tripathy D, et al. Multinational study of the efficacy and safety of trastuzumab as a single agent in the first line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719–726
  15. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792
  16. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23(19):4265–4274
  17. Viani GA, Afonso SL, Stefano EJ, et al. Adjuvant trastuzumab in the treatment of HER2-positive early breast cancer – a meta-analysis of published randomised trials. BMC Cancer. 2007;7:153
  18. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormone therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717
  19. Kaufman B, Mackey JR, Clemens M, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol. 2009;27(33):5529–5537

PII: S0936-6555(10)00057-9

doi: 10.1016/j.clon.2010.02.011

Clinical Oncology
Volume 22, Issue 4 , Pages 289-293 , May 2010

Article Tools